Compare IIF & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIF | NTHI |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.5M | 221.5M |
| IPO Year | N/A | N/A |
| Metric | IIF | NTHI |
|---|---|---|
| Price | $24.37 | $10.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.4K | ★ 69.8K |
| Earning Date | 01-01-0001 | 02-23-2026 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.95 | $3.20 |
| 52 Week High | $24.41 | $25.00 |
| Indicator | IIF | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 61.91 |
| Support Level | $24.20 | $9.05 |
| Resistance Level | $24.59 | $10.05 |
| Average True Range (ATR) | 0.30 | 1.07 |
| MACD | 0.17 | 0.12 |
| Stochastic Oscillator | 87.76 | 75.85 |
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).